Navigation Links
StemCyte, Inc. Ranked Number Six in Deloitte's Technology Fast 50 Program for Los Angeles
Date:10/3/2007

Increasing Acceptance of Umbilical Cord Blood Stem Cells as a Curative

Therapy Driving Growth

ARCADIA, Calif., Oct. 3 /PRNewswire/ -- StemCyte, Inc. has been named to Deloitte's prestigious Technology Fast 50 Program for Los Angeles, a ranking of the 50 fastest growing technology, media, telecommunications, and life sciences companies in the area by Deloitte & Touche USA LLP, one of the nation's leading professional services organizations. Rankings are based on the percentage revenue growth over five years from 2002-2006.

StemCyte's CEO Ken Giacin credits growing acceptance of umbilical cord blood stem cells for transplantation and StemCyte's outstanding record of favorable clinical outcomes for patients with leukemia and other blood diseases for the Company's excellent growth record.

Giacin said, "StemCyte has become one of the largest and most racially diverse cord blood banks in the world. This award represents the excellence of StemCyte's employees and the steadfast support of the transplant physician community."

StemCyte's increase in revenues of 1888% from 2002 to 2006 resulted in the company being the #1 fastest growing biotechnology company in the Technology Fast 50 for Los Angeles. "Deloitte's Los Angeles Technology Fast 50 companies have shown the strength, vision and tenacity to succeed in today's very competitive technology environment," said Tony Buzzelli, Vice Chairman and Regional Managing Partner, Pacific Southwest Region, Deloitte & Touche LLP. "We applaud the successes of StemCyte and acknowledge it as one of the very few to accomplish such a fast growth rate over the past five years."

To qualify for the Technology Fast 50, companies must have had operating revenues of at least $50,000 in 2002 and $5,000,000 in 2006, be headquartered in North America, and be a company that owns proprietary technology or proprietary intellectual property that contributes to a significant portion of th
'/>"/>

SOURCE StemCyte, Inc.
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine news :

1. Scotland Ranked As Sickest Area Of UK: Survey
2. U.S. Ranked Poor In Health Care Systems
3. Increase in the Number of Cases of Animal Diseases in New South Wales.
4. Human gene number increases
5. China reports declining number of SARS Cases
6. Reducing Number Of Cigarettes Not Enough
7. An Increase In Number Of Lung Cancer Deaths in Women
8. Estimates For Number Of HIV/AIDS Deaths In India Still Not Available
9. Number Of Babies Born Prematurely Nears Historic Half Million Mark In US
10. Infertility rate in UK men increasing at an alarming rate with numbers rising over 2.5 million
11. Smokers Are Prone To Number Of Psychiatric Disorders

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/4/2009)..., ORLANDO, Fla., Dec. 4 , ,What:...a,s largest Medicare, health benefit... ( http://humanagames.com ), a senior-friendly da... Guidance Center on Tues., Dec. 8 a... free and open to the public, will feature...
(Date:12/4/2009)...ION, N.J., Dec. 4 PLUS Diagnostic...lty anatomic pathology services with the launch of...service completes the company,s expansion from a r...pathology company offering diagnostic services acr...terology, urology and now hematology/oncology. ,...
(Date:12/4/2009)...EATTLE, Dec. 4 The National Cancer...ear contract to Fred Hutchinson Cancer Research Ce...ancer Information Service Contact Center. ,, Th...enter - nearly tripling the size of its current CI...y operational, which is scheduled for March 15, 20...
(Date:12/4/2009)... Lexi-Comp,s multi-language patient educa...to establish standards for language access in heal...udson, OH (PRWEB) December 5, 2009 -- Lexi-Comp, I... solutions, and patient education materials for he...of effective communication between the health care...
(Date:12/4/2009)...ren less likely to get herpes zoster virus, study ...) -- Children who are vaccinated against chicken p...gles, new findings suggest. , U.S. researchers ...n southern California who were vaccinated with the...2008. , Over an average of 2.5 years after rece...
Breaking Medicine News(10 mins):Health News:Humana Launches Dancetown on Tues., Dec. 8 in Kissimmee 2Health News:PLUS Diagnostics Launches Hematology/Oncology Diagnostic Services 2Health News:PLUS Diagnostics Launches Hematology/Oncology Diagnostic Services 3Health News:Hutchinson Center Wins $55.4 Million Contract to Become Sole Operator of the NCI Cancer Information Service 2Health News:Lexi-Comp Focused on Improving Patient Communication in Healthcare Institutions Treating Diverse Patient Populations 2Health News:Lexi-Comp Focused on Improving Patient Communication in Healthcare Institutions Treating Diverse Patient Populations 3
...oimmune disease is a condition in which the immune...gressively as it would attack a foreign pathogen. ... autoimmune disease, and is one of the most common...ttack the central nervous system. It has long been...
...lty from the University of Michigan , University... key collaborators in study , , DETROIT, April ...ecently discovered a chemical that plays a major r...rofessor of psychiatry in the School of Medicine a...
...-Week Data Supports Long-term Use of Vectical(TM) ... Patients - , , FORT WORTH, Texas, April 30 Gald...om a newly published clinical trial in this month,...o-moderate chronic plaque psoriasis. Of those pati...
...ches Women of Hope is Beautiful Campaign to Inspir...confidence, control, community, caring -- ask any...ly find meaning in these words. They are also inte...ent. The program, which is celebrating its 20th an...
...st radiosurgery solutions from Elekta discussed ...t the 2009 American Association of Neurological Su...iego Convention Center, Elekta customers and perso...nd oncologists today. , , Local Control of Brain...
...INTON, Mass., April 30 Alseres Pharmaceuticals, I... that on April 24, 2009 it entered into an Amendme...Therapeutic, Inc. (BioAxone), pursuant to which th...amended. The Amendment replaces all of the pre-co...
Other Medicine News:Health News:Gray matter under attack in multiple sclerosis 2Health News:Gray matter under attack in multiple sclerosis 3Health News:Wayne State University and Children's Hospital of Michigan Research Team Discover Chemical That Plays a Major Role in Pediatric Obsessive-Compulsive Disorder 2Health News:Wayne State University and Children's Hospital of Michigan Research Team Discover Chemical That Plays a Major Role in Pediatric Obsessive-Compulsive Disorder 3Health News:Wayne State University and Children's Hospital of Michigan Research Team Discover Chemical That Plays a Major Role in Pediatric Obsessive-Compulsive Disorder 4Health News:Study Results Published in CUTIS Demonstrate Long-Term Safety and Efficacy of Vectical(TM) (calcitriol) Ointment 3 mcg/g in the Management of Mild-to-Moderate Plaque Psoriasis 2Health News:Study Results Published in CUTIS Demonstrate Long-Term Safety and Efficacy of Vectical(TM) (calcitriol) Ointment 3 mcg/g in the Management of Mild-to-Moderate Plaque Psoriasis 3Health News:Study Results Published in CUTIS Demonstrate Long-Term Safety and Efficacy of Vectical(TM) (calcitriol) Ointment 3 mcg/g in the Management of Mild-to-Moderate Plaque Psoriasis 4Health News:Photos: Look Good. . .Feel Better Celebrates 20 Years of Helping Women Cope With Cancer 2Health News:Photos: Look Good. . .Feel Better Celebrates 20 Years of Helping Women Cope With Cancer 3Health News:Photos: Look Good. . .Feel Better Celebrates 20 Years of Helping Women Cope With Cancer 4Health News:Elekta Radiosurgery Solutions are Creating New Possibilities for the Most Challenging Cases of the Head And Body 2Health News:Elekta Radiosurgery Solutions are Creating New Possibilities for the Most Challenging Cases of the Head And Body 3Health News:Alseres and BioAxone Amend License Agreement for Cethrin(R) and Rho Inhibitor Technology 2Health News:Alseres and BioAxone Amend License Agreement for Cethrin(R) and Rho Inhibitor Technology 3Health News:Alseres and BioAxone Amend License Agreement for Cethrin(R) and Rho Inhibitor Technology 4
(Date:12/3/2009)... Ted Karkus, Chairman an... www.quigleyco.com announced today that the Comp...ies to develop prescription pharmaceutical and OTC... interests to focus primarily on the OTC/Personal ...mited to its Cold-EEZE® and Kids-EEZE® b...
(Date:12/3/2009)...rk and SAN DIEGO, California, December 3 /PRNewswi...miR-122, a microRNA Important for,Hepatitis C Vira...titis C,Virus in the Bloodstream in Chimpanzees Ch..., - SPC3649 Demonstrates Efficacy With No Evi...vents in the Treated Animals - Signaling a Potenti...
(Date:12/3/2009)...re-FirstCall/ -- Cardium Therapeutics (NYSE Amex: ...diary, Tissue Repair Company, submitted a 510(k) p...d Drug Administration (FDA) seeking marketing clea...sed on positive data from the Company,s recently c...submission with the FDA covers Excellagen XL(TM) ...
Breaking Medicine Technology:Quigley CEO, Ted Karkus, Announces Phase One of 2010 Strategic Plan; Karkus Reports that the Primary Focus will be on Leveraging its OTC Platform; Company Aggressively Seeking Product Acquisitions and Line Extensions which Leverage its Distribution 2Quigley CEO, Ted Karkus, Announces Phase One of 2010 Strategic Plan; Karkus Reports that the Primary Focus will be on Leveraging its OTC Platform; Company Aggressively Seeking Product Acquisitions and Line Extensions which Leverage its Distribution 3New Data Shows Breakthrough microRNA-Targeted Therapy Developed Using Santaris Pharma A/S Proprietary LNA Technology Holds Promise as New Treatment for Hepatitis C 2New Data Shows Breakthrough microRNA-Targeted Therapy Developed Using Santaris Pharma A/S Proprietary LNA Technology Holds Promise as New Treatment for Hepatitis C 3New Data Shows Breakthrough microRNA-Targeted Therapy Developed Using Santaris Pharma A/S Proprietary LNA Technology Holds Promise as New Treatment for Hepatitis C 4New Data Shows Breakthrough microRNA-Targeted Therapy Developed Using Santaris Pharma A/S Proprietary LNA Technology Holds Promise as New Treatment for Hepatitis C 5Cardium Files FDA 510(k) Application for U.S. Marketing Clearance of ExcellagenXL(TM) Topical Gel and ExcellagenFX(TM) Flowable Collagen Protein-Based Matrix for Diabetic, Pressure and Venous Ulcers and Other Dermal Wounds 2Cardium Files FDA 510(k) Application for U.S. Marketing Clearance of ExcellagenXL(TM) Topical Gel and ExcellagenFX(TM) Flowable Collagen Protein-Based Matrix for Diabetic, Pressure and Venous Ulcers and Other Dermal Wounds 3Cardium Files FDA 510(k) Application for U.S. Marketing Clearance of ExcellagenXL(TM) Topical Gel and ExcellagenFX(TM) Flowable Collagen Protein-Based Matrix for Diabetic, Pressure and Venous Ulcers and Other Dermal Wounds 4Cardium Files FDA 510(k) Application for U.S. Marketing Clearance of ExcellagenXL(TM) Topical Gel and ExcellagenFX(TM) Flowable Collagen Protein-Based Matrix for Diabetic, Pressure and Venous Ulcers and Other Dermal Wounds 5Lure of Bottled Water May Not Be Health Driven 49525 1WellPoint to Hold Conference Call and Webcast to Discuss Second Quarter Results on July 29 2009 49523 1WellPoint to Hold Conference Call and Webcast to Discuss Second Quarter Results on July 29 2009 49523 2Make Nursing Homes More Like Home 3A Medicare 49521 1Make Nursing Homes More Like Home 3A Medicare 49521 2
...ive Insulin-Based Therapies, Market,Growth Will be...om Decision Resource...ne of the,world,s leading research and advisory fi...s that the most significant driver of growth in th...standard of care away from,regular human insulins ...
...09, SEATTLE, Aug. 12 Cell Therapeutics, Inc.,s,(...cine (SM) announced today,that planned enrollment ...rch and Treatment of Cancer (EORTC) randomized pha...ith newly diagnosed advanced or metastatic,soft ti...he primary,endpoint of the trial is progression-fr...
Other Medicine Technology:Insulin Analogues From Novo Nordisk, Eli Lilly and Sanofi-Aventis Will Drive Growth in the Type 1 Diabetes Drug Market 2Cell Therapeutics Announces that the European Organization for Research and Treatment of Cancer Completes Enrollment in Phase II Clinical Trial of Brostallicin as First Line Therapy for Advanced or Metastatic Soft Tissue Sarcoma 2Cell Therapeutics Announces that the European Organization for Research and Treatment of Cancer Completes Enrollment in Phase II Clinical Trial of Brostallicin as First Line Therapy for Advanced or Metastatic Soft Tissue Sarcoma 3Cell Therapeutics Announces that the European Organization for Research and Treatment of Cancer Completes Enrollment in Phase II Clinical Trial of Brostallicin as First Line Therapy for Advanced or Metastatic Soft Tissue Sarcoma 4Cell Therapeutics Announces that the European Organization for Research and Treatment of Cancer Completes Enrollment in Phase II Clinical Trial of Brostallicin as First Line Therapy for Advanced or Metastatic Soft Tissue Sarcoma 5Cell Therapeutics Announces that the European Organization for Research and Treatment of Cancer Completes Enrollment in Phase II Clinical Trial of Brostallicin as First Line Therapy for Advanced or Metastatic Soft Tissue Sarcoma 6
... is a national reference laboratory and a worldwid...elopment. ARUP offers an extensive test menu of hi...and anatomic pathology. Owned by the University of...n half of the nation's university teaching hospita...
... is a national reference laboratory and a worldwid...elopment. ARUP offers an extensive test menu of hi...and anatomic pathology. Owned by the University of...n half of the nation's university teaching hospita...
... is a national reference laboratory and a worldwid...elopment. ARUP offers an extensive test menu of hi...and anatomic pathology. Owned by the University of...n half of the nation's university teaching hospita...
... is a national reference laboratory and a worldwid...elopment. ARUP offers an extensive test menu of hi...and anatomic pathology. Owned by the University of...n half of the nation's university teaching hospita...
Medicine Products: